Zusammenfassung
In der Behandlung der Osteoporose gehört Vitamin D zur Basistherapie. Vitamin-D-Wirkungen auf die Kalzium- und Phosphatresorption in Darm und Niere sowie auf die Knochenmineralisation sind gut etabliert. Durch die weite Verbreitung des Vitamin-D-Rezeptors aus der Gruppe der nukleären Steroidhormonrezeptoren gibt es umfangreiche Hinweise auf pleiotrope Effekte des Liganden Vitamin D. Ein Vitamin-D-Mangel ist verbreitet und konnte in zahlreichen Studien als Risikofaktor unterschiedlichster Erkrankungen beschrieben werden. Aus der Grundlagenforschung kommen viele Hinweise auf Vitamin-D-Wirkungen auch außerhalb des Kalzium-, Phosphat- und Knochenstoffwechsels. Für viele chronische Erkrankungen laufen aktuell kontrollierte Studien mit hoch dosiertem Vitamin D. Der vorliegende Beitrag fasst die aktuellen Erkenntnisse zu Vitamin-D-Wirkungen auf die Muskulatur, den Glukosestoffwechsel bei Diabetes mellitus Typ 2 sowie auf kardiovaskuläre Erkrankungen zusammen. Ferner wird der Einfluss von Vitamin D auf das Immunsystem diskutiert, insbesondere auf Manifestation und Verlauf von Infektionen sowie von Autoimmunerkrankungen wie Diabetes mellitus Typ 1. Die publizierte Studienlage lässt zum gegenwärtigen Zeitpunkt den Schluss zu, dass ein Vitamin-D-Mangel bei diesen Erkrankungen vermieden werden soll. In diesem Zusammenhang werden optimale Dosierungsempfehlungen vorgestellt.
Abstract
Vitamin D plays an essential role in the primary therapy and prevention of osteoporosis. Established vitamin D effects are renal and intestinal resorption of calcium and phosphate for optimal bone mineral density; however, the widespread distribution of the vitamin D receptor (VDR), a member of the nuclear steroid hormone receptor family, provides extensive evidence for additional pleiotropic effects of the vitamin D ligand. Vitamin D deficiency and insufficiency are common and were reported as risk factors for a variety of diseases in observational studies. In addition, extensive research from experimental studies also illustrated extraskeletal effects of vitamin D. More randomized controlled trials are ongoing to test the effects of high dose vitamin D supplementation in numerous chronic diseases. This article summarizes the current state of knowledge regarding effects on muscle, on glucose metabolism in type 2 diabetes mellitus and on cardiovascular risk factors and diseases. Furthermore, we discuss the influence of vitamin D on the immune system, whereby vitamin D might provide beneficial effects not only for infectious but also for autoimmune diseases, such as type 1 diabetes mellitus. Current evidence leads to the conclusion that vitamin D deficiency should be avoided in these diseases. Recommendations for optimal dosage are discussed.
Literatur
Holick MF (2007) Vitamin D deficiency. New Engl J Med 357:266–281
Wallace AM, Gibson S, Hunty A de la et al (2010) Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 75:477–488
Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930 (Endocrine Society Chevy Chase, MD)
Murad MH, Elamin KB, Abu Elnour NO et al (2011) Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:2997–3006
Rosen CJ, Adams JS, Bikle DD et al (2012) The nonskeletal effects of vitamin D: an endocrine society scientific statement. Endocr Rev 33:456–492
Stockton KA, Mengersen K, Paratz JD et al (2011) Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int 22:859–871 (a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA)
Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ et al (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 1–10
Pittas AG, Chung M, Trikalinos T et al (2010) Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 152:307–314
Hurst PR von, Stonehouse W, Coad J (2010) Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient – a randomised, placebo-controlled trial. Br J Nutr 103:549–555
Seida JC, Mitri J, Colmers IN et al (2014) Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 99:3551–3560
Herrmann M, Sullivan DR, Veillard A‑S et al (2015) Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 38:521–528
ClinicalTrials.gov Identifier: NCT01741181
Kendrick J, Targher G, Smits G et al (2009) 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 205:255–260
Dobnig H, Pilz S, Scharnagl H et al (2008) Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349
Wong MSK, Leisegang MS, Kruse C et al (2014) Vitamin D promotes vascular regeneration. Circulation 130:976–986
Bolland MJ, Grey A, Avenell A et al (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ 342:d2040–d2040
Chung M, Lee J, Terasawa T et al (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 155:827–838
Trivedi DP, Doll R, Khaw K‑T (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469–469
Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696
Lewis C, Xun P, He K (2015) Vitamin D supplementation and quality of life following diagnosis in stage II colorectal cancer patients: a 24-month prospective study. Support Care Cancer 1–7
Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58
Kearns MD, Alvarez JA, Seidel N et al (2015) Impact of vitamin D on infectious disease. Am J Med Sci 349:245–262
Sudfeld CR, Giovannucci EL, Isanaka S et al (2013) Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy. J Infect Dis 207:378–385
Coelho L, Cardoso SW, Luz PM et al (2015) Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy. Nutr J 14:81
Farnik H, Bojunga J, Berger A et al (2013) Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology 58:1270–1276
Chan HL-Y, Elkhashab M, Trinh H et al (2015) Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol 63:1086–1092
Kitson MT, Sarrazin C, Toniutto P et al (2014) Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol 61:1247–1252
Reich KM, Fedorak RN, Madsen K et al (2014) Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol 20:4934–4947
Wolden-Kirk H, Overbergh L, Christesen HT et al (2011) Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol 347:106–120
Mathieu C, Waer M, Laureys J et al (1994) Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37:552–558
Dong J‑Y, Zhang W‑G, Chen JJ et al (2013) Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients 5:3551–3562
Ataie-Jafari A, Loke S‑C, Rahmat AB et al (2013) A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr 32:911–917
Walter M, Kaupper T, Adler K et al (2010) No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 33:1443–1448
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
K. Badenhoop wird von der Else Kröner-Fresenius Stiftung (EKFS) im Rahmen des Promotionskollegs Translational Research Innovation-Pharma (TRIP) gefördert; es besteht kein Interessenkonflikt. F. Schlereth gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
H. Lehnert, Lübeck
M. Reincke, München
Caption Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Schlereth, F., Badenhoop, K. Vitamin D. Internist 57, 646–655 (2016). https://doi.org/10.1007/s00108-016-0082-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-016-0082-2
Schlüsselwörter
- Herz-Kreislauf-Erkrankungen
- Muskelschwäche
- Infektionen
- Diabetes mellitus
- Hormonersatztherapie, Vitamin D